Novocure Ltd (NASDAQ:NVCR) insider Pritesh Shah sold 8,988 shares of Novocure stock in a transaction that occurred on Wednesday, January 9th. The stock was sold at an average price of $40.00, for a total transaction of $359,520.00. Following the completion of the sale, the insider now directly owns 26,075 shares of the company’s stock, valued at approximately $1,043,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Pritesh Shah also recently made the following trade(s):

  • On Wednesday, December 12th, Pritesh Shah sold 38,781 shares of Novocure stock. The stock was sold at an average price of $36.00, for a total transaction of $1,396,116.00.

Shares of NVCR stock traded up $1.25 during mid-day trading on Friday, reaching $43.25. 876,930 shares of the company’s stock traded hands, compared to its average volume of 791,356. Novocure Ltd has a 12 month low of $19.06 and a 12 month high of $53.70. The company has a debt-to-equity ratio of 1.30, a current ratio of 6.17 and a quick ratio of 5.72. The company has a market cap of $3.76 billion, a price-to-earnings ratio of -61.79 and a beta of 2.86.

Novocure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, October 25th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. Novocure had a negative net margin of 25.37% and a negative return on equity of 52.72%. The firm had revenue of $64.76 million during the quarter, compared to the consensus estimate of $65.61 million. Equities research analysts expect that Novocure Ltd will post -0.68 EPS for the current year.

Several hedge funds have recently modified their holdings of NVCR. FMR LLC grew its position in shares of Novocure by 37.9% during the 3rd quarter. FMR LLC now owns 10,845,246 shares of the medical equipment provider’s stock valued at $568,292,000 after acquiring an additional 2,983,125 shares during the period. BlackRock Inc. grew its position in shares of Novocure by 22.4% during the 2nd quarter. BlackRock Inc. now owns 4,620,546 shares of the medical equipment provider’s stock valued at $144,623,000 after acquiring an additional 846,277 shares during the period. Macquarie Group Ltd. grew its position in shares of Novocure by 89.0% during the 3rd quarter. Macquarie Group Ltd. now owns 1,104,117 shares of the medical equipment provider’s stock valued at $57,856,000 after acquiring an additional 519,988 shares during the period. Renaissance Technologies LLC grew its position in shares of Novocure by 276.3% during the 2nd quarter. Renaissance Technologies LLC now owns 682,603 shares of the medical equipment provider’s stock valued at $21,365,000 after acquiring an additional 501,203 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Novocure by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 5,424,908 shares of the medical equipment provider’s stock valued at $284,265,000 after acquiring an additional 476,635 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have commented on NVCR. BidaskClub raised shares of Novocure from a “hold” rating to a “buy” rating in a research report on Friday. ValuEngine raised shares of Novocure from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Zacks Investment Research downgraded shares of Novocure from a “hold” rating to a “sell” rating in a research report on Saturday, December 29th. Mizuho reaffirmed a “buy” rating and issued a $51.00 target price on shares of Novocure in a research report on Thursday, December 6th. Finally, Wells Fargo & Co downgraded shares of Novocure from an “outperform” rating to a “market perform” rating in a research report on Friday, November 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $48.00.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://theolympiareport.com/2019/01/11/novocure-ltd-nvcr-insider-sells-359520-00-in-stock.html.

Novocure Company Profile

Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.

Further Reading: What is cost of equity?

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.